15 results
10-K
2020 FY
KROS
Keros Therapeutics Inc
25 Mar 21
Annual report
8:23am
to be vasodilation. Accordingly, we believe there is a significant unmet need for a treatment that primarily
targets the proliferative pathological processes and can … to seek patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets, and that may
424B4
KROS
Keros Therapeutics Inc
13 Nov 20
Prospectus supplement with pricing info
4:02pm
to be vasodilation. Accordingly, we believe there is a significant unmet need for a treatment that primarily targets the proliferative pathological processes … to discover and validate targets, and that may be used to manufacture and develop novel products. We are a party to license agreements that give us rights
8-K
EX-99.1
w0ivdlwjtyso2u2cp8x
10 Nov 20
Other Events
5:14pm
DRS
i7sdsgrtt
3 Nov 20
Draft registration statement
12:00am
8-K
EX-99.1
v1ff34eq83ow1jewhho
8 Sep 20
Corporate Presentation September 2020
8:04am
8-K
EX-99.1
fiiblwsus9
2 Jun 20
Corporate Presentation June 2020
4:19pm
424B4
rhe7gw
8 Apr 20
Prospectus supplement with pricing info
4:58pm
S-1
uqlihn20
16 Mar 20
IPO registration
4:57pm
DRS/A
fr3eq6n4qyr4n c4p
27 Feb 20
Draft registration statement (amended)
12:00am
DRS
vpm 2y3l6wz
21 Jan 20
Draft registration statement
12:00am
- Prev
- 1
- Next